Description
UrgoClean Ag is an innovative dressing in nonwoven, absorbent and gelling fabric, made up of poly-absorbent polyacrylate fibers that guarantee a complete detersion and debridement action (from slough, fibrin, exudated, bacterial residues and biofilm) and a TLC-Ag colloidal lipid matrix that performs antimicrobial action. The combined action of the TLC-Ag matrix and poly-absorbent fibers allows an antimicrobial, anti-biofilm and full detersion action.
- UrgoClean TLC-Ag matrix Ag gels in contact with the exudate of the lesion, reducing the bacterial charge of the lesion with a rapid and broad spectrum action (tested on 36 bacterial strains and 4 yeasts, including bacterial strains resistant to antibiotics-MRSA, ERV, ESBL).
- In contact with injury, the poly-absorbent fibers of UrgoClean Ag gels and breaks the matrix of the biofilm, allowing silver ions to perform their bactericidal action within the biofilm. The combined action of poly-absorbent fibres and TLC-Ag matrix has proven to effectively reduce the concentration of MRSA and MRSA sessile bacteria P.aeruginosa within 24 hours and during 7 days (reduction of biofilm > 99.99%). The anti-biofilm action of UrgoClean Ag is superior to the Idrofibra Ag+Extra and compared to the dressing with DACC.
- UrgoClean Ag removes all those factors that favor bacterial proliferation and which can limit the action of silver. The poly-absorbent fibers of UrgoClean Ag absorb and trap slough, exudated and biofilm residues through an electrostatic mechanism. UrgoClean Ag has clinically demonstrated after 4 weeks of treatment to reduce slough by 62.5% and to deter 59% of lesions (deterred injury = covered injury with less than 30% slough).
- The dressing is removed in a piece thanks to the acrylic core present in poly-absorbent fibers.
- UrgoClean Ag ensures atraumatic and painless care thanks to the wet environment provided by the TLC-Ag3 matrix.
- UrgoClean manages mild bleeding due to hemostatic properties.
- UrgoClean Ag is cut out and can be used with a secondary dressing.
- UrgoClean Ag can be combined with a compressed therapy when prescribed.

Composition
Antimicrobial medicine composed entirely of poly-absorbent fibers in polyacrylate, detergents and gelling agents, and a micro-adhesive collidal lipid matrix TLC-Ag (TLC-Ag: Lipido-Colloidal technology, composed of carboxylcellulose particles, lipid substances and silver salts) to combat the local infection through a combined action. UrgoClean Ag has the ability to cleanse and maintain the deterred lesion.

Mode of use
Determine the lesion using the conventional treatment protocol, then rinse with physiological solution. If, previously, an antiseptic was used, carefully rinse the lesion with physiological solution before applying UrgoClean Ag. Use of UrgoClean Ag does not leave the need for mechanical operation if necessary. Remove protective tabs and apply the micro-adhesive part of UrgoClean Ag in contact with injury and perilesional skin. If necessary, you can cut UrgoClean Ag with sterile scissors to adapt the size of the dressing to that of the injury. It is recommended to use a bandage to fix the dressing and ensure that it remains in place. Also, it is possible to cover UrgoClean Ag with a secondary dressing suitable for the position of the injury and the degree of excision. If prescribed, apply compressed therapy. UrgoClean dressing Ag must be replaced every 1-2 days at the beginning of the treatment, and subsequently when necessary (up to 7 days) depending on the amount of exudate and the clinical state of the injury. Treatment with Urgoclean Ag should not extend more than a month.
The TLC-Ag micro-stick matrix in UrgoClean Ag can adhere to latex surgical gloves. Therefore it is recommended to moisten the gloves with normal saline solution to handle the dressing more easily. During the process of hurrying, the injury may seem bigger than usual. This is due to the effective removal of slough.

Warnings
Contraindicated in cases of sensitivity known to silver.
UrgoClean Ag is not recommended to be used as a surgical sponge for highly exudatory injuries.
Do not use UrgoClean Ag in combination with oxygen peroxide, organ-mercury-based antiseptics or antiseptics containing examination.
Do not use Open Magnetic Resonance (RMA) patients.
Treatment with UrgoClean Ag must be performed under medical control.
The use of UrgoClean Ag does not require a systemic antibacterial treatment for infection, in line with the local protocol.
Concurrent use with other local treatments is not recommended.
Avoid contact with electrodes or conductive gels used in case of EEG or ECG.
Healthcare staff should be informed of poor information, poor specific data on prolonged and repeated use of silver dressings, especially in children and infants.
In the absence of specific clinical data, use in pregnant women or during breastfeeding is not recommended.
Individual sterile packaging, only disposable: reuse of a disposable packaging can lead to infection risks.
Do not resterilize the dressing.
Before use, make sure the sterile protection film is intact. Do not use in case of damaged packaging.

Conservation
Store at room temperature away from light and heat sources.
Validity of whole packaging: 36 months.

Format
Available in:
-5 pieces package, size: 6 cm x 6 cm;
-5 pieces package, size: 10 cm x 10 cm;
-5 pieces package, size: 15 cm x 15 cm;
-10 pieces package, size: 6 cm x 6 cm;
-10 pieces package, size: 10 cm x 10 cm;
-10 pieces package, size: 15 cm x 15 cm.

Cod. 552093, 552273, 552095, 552094, 552274, 551749

Bibliography
Lazareth I., et al., The Role of a Silver Releasing Lipido-colloid Contact Layer in Venous Leg Ulcers Presenting Inflammatory Signs Suggesting Heavy Bacterial Colonization: Results of a Randomized Controlled Study. WOUNDS 2008;20 (6):158–166.
Meaume S., et al., Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, Vol 23, No 3, March 2014, 105-116.
Dalac S., et al., Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix managing chronic wounds at risk of infection: a non-comparative trial. J Wound Care, Vol 25, No 9, September 2016.
J. Dissemond, Results of a national multicentre observational trial on desloughing properties on wounds at risk or with signs of a local infection with a polyabsorbent dressing with silver. Oral communication. EWMA 2017.
Desroche N. et al., Characterization of the antimicrobial spectrum and anti-biofilm activity of a new silver-containing dressing with poly-absorbent fibres and antimicrobial silver matrix. Poster EWMA May 2016.
Desroche N., et al., Antibacterial properties and reduction of MRSA biofilm with a dressing combining poly-absorbent fibres and a silver matrix. J Wound Care, Vol 25, No 10, October 2016.
Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care. 2018 Feb;27(2): 102-13.
Desroche N. et al, Evaluation of in vitro anti-biofilm activities of two dressings with poly-absorbent dressing fibres and a DACC-coated dressing. Poster EWMA 2017.
UrgoClean Ag data on file.
Pernot JM, et al., Interactions between poly-absorbent fibres and fibrin. Poster Journées Cicatrisations. January 2017.
Percival SL, et al. Slough and biofilm: removal of barriers to wound healing by desloughing. J Wound Care. 2015 Nov;24 (11):498,500-3,506-10.